Health
Question mark over effectiveness of Pfizer-BioNTech COVID-19 vaccine in obese people – BioPharma-Reporter.com
New data may have serious implications for the development of vaccination strategies for COVID-19, particularly in individuals with obesity.
A study by a team of researchers based at Istituti Fisioterapici Ospitalieri (IFO) in Rome, Italy, aimed to analyse the antibody response following two doses of the Pfizer/BioNTech COVID-19 vaccine, BNT162B2, in 248 healthcare workers. They also looked to evaluate how the antibody titer in those participants changed in relation to age, gender and body mass index (BMI).
Of the cohort studied, 158 were women (63.7%) and 90 were men (36.3%). The average age was 47 years, with the range going from 23…
-
General19 hours agoWondering about winter | The Spectator Australia
-
Noosa News18 hours agoJane Bunn weather: Cyclone Errol forms as effects of Alfred still felt across Queensland
-
Business23 hours agoAre Domain Holdings shares undervalued?
-
Business21 hours agoWiseTech shares lift off amid agreement with founder Richard White